A Brake Becomes an Accelerator: PTP1B—A New Therapeutic Target for Breast Cancer  by Tonks, Nicholas K. & Muthuswamy, Senthil K.
Cancer Cell
PreviewsA Brake Becomes an Accelerator: PTP1B—A 
New Therapeutic Target for Breast Cancer




The protein tyrosine phosphatase PTP1B, previously recognized for its role in downregulating insulin 
and leptin signaling, has now been shown to function as a positive regulator of signaling events asso-
ciated with breast tumorigenesis. Inhibitors of PTP1B that have been developed as drug candidates 
for treatment of diabetes and obesity may offer new avenues for the treatment of breast cancer.ErbB2  (HER2,  Neu)  is  a 
protein  tyrosine  kinase 
(PTK)  of  the  EGF  recep-





events  initiated  by  ErbB2, 
and  the  mechanisms  by 
which  they  are  regulated, 






(Hynes  and  Lane,  2005). 
Two  recent  papers  have 
revealed an  important  role 
for  PTP1B,  the  prototypic 
member of the protein tyro-
sine  phosphatase  (PTP) 
superfamily,  as  a  positive 





PTP1B  has  been  impli-
cated  in  downregulation 
of  signaling  through  sev-
eral  RPTKs.  In  particular, 
ptp1B  knockout  mice  dis-
play a striking phenotype—
enhanced  sensitivity  to  insulin  and 





the  abrogation  of  PTP1B’s  function 214  Cancer Cell 11, March 20Figure 1. PTP1B Exerts a Positive Effect on ErbB2-Induced 





GAP.  It  has  been proposed  that PTP1B dephosphorylates  p62Dok, 
thereby attenuating  its  inhibitory effects on Ras activation and pro-
moting MAP kinase signaling. PTP1B also plays a positive role in the 






PI3 kinase signaling is unclear.07 ©2007 in  downregulating  signaling  through 
insulin  and  leptin  receptors.  Conse-
quently, the development of inhibitors 
of  PTP1B  has  become  a  high  prior-
ity  in the pharmaceutical  industry as 
a  novel  therapeutic  strategy  for  the 












gene  is  located  at  20q13, 
a  region  that  is  frequently 
amplified  in  breast  cancer 










utilized  NDL2  mice,  which 
express an activated mutant 
of  ErbB2  bearing  a  five 
amino  acid  in-frame  dele-
tion in the extracellular seg-
ment  under  the  control  of 
the mouse mammary tumor 
virus  (MMTV)  promoter 
(Julien  et  al.,  2007).  These 
mice  develop  mammary tumors that display features of human 
breast  cancer.  NDL2  were  crossed 
with ptp1B knockout mice, both in FVB 






dent  effects  of  the  phosphatase.  In 
addition  to  the  delay  in  tumor  onset, 
both  ptp1B+/−  and  ptp1B−/−  mice  dis-
played  decreased  incidence  of  lung 




mice  expressing  the  transmembrane 
domain  point  mutant  form  of  ErbB2 
(V664Q)  with  ptp1B  knockout  mice, 
but on a mixed strain background (FVB 
×  129Sv:C57B6/J).  In  this  case,  the 
absence  of  PTP1B  also  led  to  a  pro-
nounced delay in tumor development, 
but no effect was observed in mice het-
erozygous  for  PTP1B  (Betires-Alj  and 
Neel, 2007).  In contrast  to  the effects 
observed  for  MMTV-NeuNT,  loss  of 
PTP1B did not alter mammary tumori-
genesis induced by polyoma middle T 
antigen,  demonstrating  specificity  in 
the effects of the phosphatase.
The  dephosphorylation  and  acti-
vation of Src  family PTKs has been 
established  as  underlying  the  func-
tion of other positively acting PTPs, 
such as CD45,  in different signaling 
contexts  (Hermiston  et  al.,  2003). 
Consistent  with  a  positive  signal-
ing  function, PTP1B has been  iden-
tified  as  the  major  phosphatase 
catalyzing  c-Src  dephosphorylation 
in  breast  cancer  cell  lines  (Bjorge 
et  al.,  2000).  However,  no  change 
in  phosphorylation  or  activation  of 
c-Src  was  observe  in  these  animal 
models  of  breast  cancer,  which 
is  consistent  with  an  earlier  study 
indicating  that  the  kinase  function 
of  Src  is  not  required  for  ErbB2-
induced  tumorigenesis  (Kaminski et 
al.,  2006).  Instead,  both  labs  noted 
that  loss  of  PTP1B  is  accompanied 
by attenuated activation of the Ras/
MAP kinase pathway. The Tremblay 
group  suggests  that  the  mecha-
nism  involves  dephosphorylation 
and  inhibition  of  p62Dok,  an  adap-
tor  protein  previously  identified  as 
a substrate of PTP1B, which down-
regulates  Ras/MAP  kinase  signal-
ing  through  its  association  with 




increased  levels  of  p120RasGAP 
protein  (Julien  et  al.,  2007).  How-
ever, changes  in p120RasGAP were 
not observed  in  the study by Neel’s 
group  (Betires-Alj  and  Neel,  2007). 
The  reason  for  this  discrepancy  is 
unclear,  but  this  and  other  differ-
ences  between  the  conclusions  of 
the two studies may reflect the differ-
ences  in mouse  strain  background, 
homogeneous  versus  mixed,  and 
possibly  also  the  different  forms  of 
activated ErbB2 that were used.
ErbB2-induced  mammary  tumors 
express  high  levels  of  ErbB3,  and 
heterodimerization  of  ErbB2  and 
ErbB3  is critical  for  signaling  to  the 
PI3  kinase/PKB  (AKT)  pathway. 
Tremblay’s  group  also  showed  that 
the  levels  of  ErbB3  and  the  phos-
phorylation  of  PKB  (Ser473)  were 
reduced  in PTP1B null  tumors.  Fur-







the  tumors.  Perhaps  most  striking 
was the observation that administra-
tion  of  an  orally  bioavailable  small-




cose  to  levels  comparable  to  those 
in  NDL2-ptp1B−/−  animals.  Overall, 
these studies lead to the same con-
clusion—PTP1B  is  an  important 




PTP1B  is  localized  on  the  cyto-
plasmic  face  of  endoplasmic  retic-
ulum  membranes  and  has  been 
implicated  in  the  dephosphoryla-
tion  and  inactivation  of  RPTKs  that 
have  undergone  endocytosis  (Haj 
et al., 2002).  It has been suggested 
that ErbB2 undergoes slow endocy-
tosis,  emphasizing  the  importance 
of  signaling  events  initiated  at  the 




after  internalization  on  endosomes, 





of  ErbB2  signaling  initiated  at  the 
endomembranes  or  due  to  regula-
tion  of  complementary  signaling 
pathways that synergize with plasma 
membrane-bound ErbB2 remains to 
be  determined.  Therefore,  it  will  be 
important  not  only  to  define  all  the 
critical  substrates  of  PTP1B  in  this 
context, but also to establish where 
such  dephosphorylation  events  are 
taking place within the cell. Although 
there  appears  to  be  a  cell-autono-
mous  component  to  the  effects  of 
PTP1B  deficiency  on  ErbB2  sig-
naling,  it  will  be  important  also  to 
assess  the contribution of non-cell-
autonomous  effects  on  tumorigen-
esis, such as potential disruption of 
immune  cell  function  in  the  PTP1B 
knockout animals.
It is now clear that the PTPs do not 
simply  function  as  passive  antago-
nists of PTKs, but rather their activ-
ity  is  coordinated  with  that  of  the 
kinases,  such  that  they  are  critical 
regulators  of  signaling  in  their  own 
right.  Recently,  the  positive  role  of 
PTPs in signaling was highlighted by 
the  identification  of  ptpN11  (SHP2) 
as  the first PTP oncogene, which  is 
mutated  in  several  leukemias  (Mohi 
and Neel, 2007). As described here, 
PTP1B has now been shown to play 
a  positive  role  in  regulating  signal-
ing  events  associated  with  breast 
tumorigenesis.  In  fact,  Tremblay’s 
group  demonstrated  that  MMTV-
directed  overexpression  of  PTP1B 
alone  was  sufficient  to  drive  mam-
mary  tumorigenesis  (Julien  et  al., 
2007).  Such  observations  highlight 
the  potential  importance  of  PTPs 




PTP1B  as  a  therapeutic  target  for 
diabetes  and  obesity.  These  have 
generated  extremely  potent  and 
selective  inhibitors  that  may  prove 1, March 2007 ©2007 Elsevier Inc.  215
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Previewseffective  in  a  cancer  context.  The 
studies highlighted here suggest the 
exciting possibility that combination 
therapies  targeting  both  ErbB2  and 
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